Loading...
XSHG603739
Market cap403mUSD
Jan 09, Last price  
11.68CNY
1D
-0.43%
1Q
4.57%
IPO
-51.09%
Name

Qingdao Vland Biotech Co Ltd

Chart & Performance

D1W1MN
XSHG:603739 chart
P/E
36.62
P/S
2.47
EPS
0.32
Div Yield, %
0.00%
Shrs. gr., 5y
9.24%
Rev. gr., 5y
8.05%
Revenues
1.20b
+3.07%
728,223,334751,723,670781,229,944799,439,774813,970,528846,777,962960,249,3541,150,823,5651,163,162,7811,198,902,103
Net income
81m
+15.56%
53,234,92070,265,77582,550,44285,625,17683,384,93877,752,946108,976,210132,573,19669,842,00780,706,911
CFO
154m
+61.16%
58,547,60074,268,465154,487,354121,900,84485,751,37965,327,125172,997,19089,513,69995,306,379153,592,321
Dividend
May 30, 20240.1 CNY/sh
Earnings
May 16, 2025

Profile

Qingdao Vland Biotech INC. engages in the research and development of enzymes, probiotics, and animal vaccines and health products. It offers animal feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological products, such as live and inactivated poultry, and swine vaccines, as well as antibodies; poultry drugs comprising anti-parastic, antiviral, and nutritional drugs, as well as disinfectants; and traditional Chinese veterinary medicines for scale and avian breeding, livestock, and laying hens. It serves agriculture, animal husbandry, textile, paper making, household cleaning and detergents, food, biofuel, environmental protection, and other industries. The company was incorporated in 2005 and is headquartered in Qingdao, China. Qingdao Vland Biotech INC. operates as a subsidiary of Qingdao Kangdien Industrial Co., Ltd.
URL
http://www.vlandgroup.com/
IPO date
Jan 16, 2019
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,198,902
3.07%
1,163,163
1.07%
Cost of revenue
920,255
973,102
Unusual Expense (Income)
NOPBT
278,648
190,060
NOPBT Margin
23.24%
16.34%
Operating Taxes
19,638
16,776
Tax Rate
7.05%
8.83%
NOPAT
259,010
173,284
Net income
80,707
15.56%
69,842
-47.32%
Dividends
(40,334)
Dividend yield
1.16%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
568,971
374,216
Long-term debt
62,060
149,000
Deferred revenue
47,955
Other long-term liabilities
55,416
172
Net debt
18,547
97,327
Cash flow
Cash from operating activities
153,592
95,306
CAPEX
(215,643)
Cash from investing activities
(298,781)
Cash from financing activities
156,360
227,722
FCF
133,803
(261,563)
Balance
Cash
531,642
425,889
Long term investments
80,843
Excess cash
552,540
367,731
Stockholders' equity
1,073,599
1,043,698
Invested Capital
1,959,294
1,911,053
ROIC
13.38%
10.04%
ROCE
11.08%
8.33%
EV
Common stock shares outstanding
252,209
258,674
Price
15.22
13.41%
13.42
-27.85%
Market cap
3,838,622
10.58%
3,471,406
-23.98%
EV
3,974,262
3,657,952
EBITDA
352,932
255,768
EV/EBITDA
11.26
14.30
Interest
15,218
7,172
Interest/NOPBT
5.46%
3.77%